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A human antibody against Zika virus crosslinks the
E protein to prevent infection
S. Saif Hasan1, Andrew Miller1, Gopal Sapparapu2,3, Estefania Fernandez4, Thomas Klose1, Feng Long1,
Andrei Fokine1, Jason C. Porta1, Wen Jiang1,5, Michael S. Diamond4,6,7,8, James E. Crowe Jr.2,3,9,
Richard J. Kuhn1,5 & Michael G. Rossmann1,5
The recent Zika virus (ZIKV) epidemic has been linked to unusual and severe clinical
manifestations including microcephaly in fetuses of infected pregnant women and
Guillian-Barre´ syndrome in adults. Neutralizing antibodies present a possible therapeutic
approach to prevent and control ZIKV infection. Here we present a 6.2Å resolution
three-dimensional cryo-electron microscopy (cryoEM) structure of an infectious ZIKV
(strain H/PF/2013, French Polynesia) in complex with the Fab fragment of a highly
therapeutic and neutralizing human monoclonal antibody, ZIKV-117. The antibody had been
shown to prevent fetal infection and demise in mice. The structure shows that ZIKV-117 Fabs
cross-link the monomers within the surface E glycoprotein dimers as well as between
neighbouring dimers, thus preventing the reorganization of E protein monomers into
fusogenic trimers in the acidic environment of endosomes.
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Z
ika virus (ZIKV) is a member of the Flaviviridae family of
positive-stranded RNA viruses, which includes well-known
human pathogens such as dengue (DENV), yellow
fever (YFV), West Nile (WNV) and Japanese encephalitis (JEV)
viruses1. ZIKV was ﬁrst identiﬁed in sentinel rhesus monkeys
in Uganda in 1947 (ref. 2), in mosquitoes in 1948 (ref. 2) and
was ﬁrst isolated from humans in 1952 (ref. 3). The ﬁrst
major outbreak of the virus was recorded in 2007 in Micronesia4
and then in 2013–2014 in Oceania5. The latest outbreak,
which started in Brazil in 2014–2015 (ref. 6), has spread to
other countries in South America, North America and the
Caribbean7.
Flaviviruses contain an RNA genome (B11 kb) that is enclosed
within the viral capsid. The nucleocapsid complex is enclosed
within an icosahedral shell formed by 180 copies of each of the
envelope (‘E’,B500 residues) and membrane (‘M’,B75 residues)
glycoproteins. The M protein is a product of cleavage of the
precursor M (‘prM’, B165 residues) protein. Cryo-electron
microscopy (cryoEM) structures of mature ZIKV (refs 8,9)
showed a typical ‘herringbone’ arrangement of the E proteins on
the viral surface, which is a characteristic of mature ﬂaviviruses10.
Following cellular entry, ﬂaviviruses assemble ﬁrst as ‘spiky’,
non-infectious immature particles with 60 trimeric spikes of
E:prM heterodimers11,12. The immature particles undergo
maturation into smooth infectious particles, which involves
the cleavage of the prM protein into pr and M. The E and
M glycoproteins are reorganized into 90 dimers11,12. Upon release
into the extracellular environment, the pr peptide dissociates
from the ﬂavivirus surface to yield smooth, mature, infectious
particles11,13.
ZIKV infections were previously associated with only a rash
and mild ﬂu-like symptoms until the latest epidemic, during
which a link was established between ZIKV infection and
paralytic Guillian-Barre´ syndrome in adults14, and fetal
abnormalities in pregnant women, including microcephaly15,16.
Four cases of fetal deformities have been reported in December
2016 in New York City17. In contrast to other ﬂaviviruses that
are spread mainly by arthropod vectors, recent evidence suggests
that ZIKV can be transmitted sexually and vertically in addition
to transmission by mosquitoes18,19. Given the severity of the
symptoms caused by ZIKV infection in humans, it is crucial to
understand the immune response elicited by ZIKV infection to
develop neutralizing anti-ZIKV therapies. A recent study
identiﬁed a human monoclonal antibody (mAb), ZIKV-117,
that was demonstrated to possess therapeutic potential, with no
cross-reactivity to other ﬂaviviruses20. This is signiﬁcant as ZIKV
antibodies that cross-react with DENV have been shown to
promote DENV infection by antibody dependent enhancement21.
The mAb ZIKV-117 neutralizes ZIKV strains that belong to
African, Asian and American lineages and is able to reduce fetal
infection and death in mice. However, the mechanisms of
neutralization of ZIKV infection by mAb ZIKV-117 and the
structural basis for broad-range neutralization of ZIKV strains,
while showing no cross-reactivity with other ﬂaviviruses, had
remained unknown.
Here we present a cryoEM map of ZIKV strain H/PF/2013 in
complex with ZIKV-117 Fab at a resolution of 6.2 Å. The map
showed that the mechanism of virus neutralization was by
binding of Fab fragments that cross-linked the E monomers
within dimers and also cross-linked neighbouring dimers in the
viral glycoprotein shell. However, the binding of any one of the
Fab molecules excluded binding of a Fab to any of the other
chemically equivalent sites in the icosahedral asymmetric unit.
Thus, saturation is achieved by binding of only 60 Fabs to the
180 chemically equivalent sites on the virus, greatly reducing the
concentration of the antibody needed for neutralization.
Results
The cryoEM structure of ZIKV complexed with ZIKV-117 Fab.
Mature ZIKV was puriﬁed from Vero cells over-expressing the
enzyme furin8. MAb ZIKV-117 was isolated from a B cell in
a peripheral blood sample, obtained from an otherwise healthy
human subject with previous history of symptomatic ZIKV
infection20. The ZIKV particles were incubated with Fab
fragments of ZIKV-117, ﬂash-frozen on lacey carbon EM grids
and imaged using a Gatan K2 direct electron detector attached
to a Titan-Krios microscope. After automated selection of
virus-Fab particles, a data set containing 8,153 virus-Fab
complexes was split into two halves to perform two indepe-
ndent 3D-reconstructions for a ‘gold-standard’ evaluation of the
resolution22. The previously published ZIKV cryoEM map8 was
low-pass ﬁltered to 50Å resolution, and used as the initial model
for single particle reconstruction by the program jspr (ref. 23).
The ﬁnal map had a resolution of 6.2 Å corresponding to a
Fourier Shell Correlation coefﬁcient of 0.143 (ref. 24)
(Supplementary Fig. 1). The cryoEM map (Fig. 1) was
interpreted by ﬁtting of E protein and Fab coordinates with the
programs Chimera25, Coot26 and EMﬁt27 following the original
procedure ﬁrst used to determine the structure of DENV10. The
icosahedral asymmetric unit of the ZIKV structure contains three
copies of the E protein, whose ectodomain is organized into three
domains, DI, DII and DIII (ref. 28) (Supplementary Fig. 2a,b).
The structure of a ZIKV E dimer (Protein Data Bank, PDB
ID 5IRE, residues 1–396) (ref. 8) was ﬁtted into the cryoEM
map by superposing the dimer two-fold axis onto an icosahedral
two-fold axis (‘i2 axis’) (Fig. 2, monomers A and A0) using the
Chimera and EMﬁt programs. This dimer will be referred to as
the icosahedral E dimer (‘i2 dimer’). A second E dimer (Fig. 2,
monomers C and E) was ﬁtted at a general position, where
the cryoEM map appears to have a quasi two-fold axis (‘q2 axis’,
Fig. 2, yellow oval). This dimer will be referred to as the general
5f
2f 3f
Figure 1 | CryoEM map of ZIKV/ZIKV-117. The ZIKV-Fab surface is shown
in radial colouring, from yellow (B210Å) to red (B290Å). The bound Fab
(red ‘knobs’) extends from the surface of ZIKV, which is shown in yellow.
The Fab sites close to the two-fold (‘2f’), three-fold (‘3f’) and
ﬁve-fold (‘5f’) axes are labelled. The icosahedral 2 (oval), 3 (triangle) and
5 (pentagon) fold axes are marked in blue shapes with black outlines, and
a representative asymmetric unit is shown as a black triangle.
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E dimer (‘q2 dimer’). As the asymmetric unit contains
three copies of the E protein (Fig. 2, monomers A, C and E), it
should be possible for three Fabs to be bound within the
asymmetric unit. However, only two prominent Fab-bound
positions were observed, one (‘2f’) closest to an i2 axis and the
other (‘3f’) closest to an icosahedral three-fold axis (‘i3 axis’)
(Figs 1 and 2). The additional density at the third chemically
equivalent position (‘5f’) closest to an icosahedral ﬁve-fold axis
(‘i5 axis’) was weak (Fig. 1). The coordinates of a ZIKV-speciﬁc
Fab (ZV-67, PDB ID 5KVG) (ref. 29) were split into the constant
and variable domains of the heavy and light chains. These
domains were ﬁtted individually into the Fab densities at the
2f and 3f sites using Chimera and Coot. As the density is
incomplete at the 5f site, Fab coordinates were placed by hand.
The average heights of electron density of the E proteins and the
Fabs were compared using the program EMﬁt.
Interference between overlapping ZIKV-117 Fab binding sites.
Within an icosahedral asymmetric unit of ZIKV, the two E protein
monomers of the general dimer (Fig. 2, monomers C and E) are
related by q2 symmetry (Fig. 2, yellow oval). The icosahedral
E dimer (Fig. 2, monomers A and A0) is similar in structure to the
general E dimer (Fig. 2, monomers C and E). As a result, the
icosahedral i2 dimer and the general q2 dimer are related by a q2
axis (Fig. 2, orange oval). Three residues of the ZIKV E protein,
Asp67, Gln89 and Lys118 (‘Asp-Gln-Lys triad’), previously deter-
mined to be in the ZIKV-117 epitope by alanine mapping20,
are located closest to the q2 axis (Fig. 2, orange oval) that relates
the i2 dimer with the general q2 dimer. The similar positions
of these three residues in the footprint of the Fabs at both the
2f and 3f sites are satisfactorily consistent with the EM results
presented here and also demonstrate the chemical equivalence of
these sites.
Binding of Fabs at the 5f sites around each ﬁve-fold axis is not
limited by overlap between Fabs bound to neighbouring 5f sites
because these sites are spatially well separated (Supplementary
Fig. 3). However, the low occupancy of Fabs at the supposedly
chemically equivalent 5f sites is readily understandable because of
the different environments of the 5f sites to the 3f and 2f sites.
The ‘road map’ (Fig. 3) shows that the 5f site is bounded at one
side by an E monomer that extends radially outwards further than
the 5f site. Therefore, the E monomer not only changes a part of
the 5f site to be different to the 3f and 2f sites, but also sterically
hinders the binding of Fabs to the 5f sites. The residual small
occupancy of the 5f sites (Fig. 1) is probably due to the inclusion
of particles in the cryoEM reconstruction that were able to bind
Fab at the 5f sites after inducing small local conformational
changes.
The footprints of Fabs when bound to the 3f and 2f sites
overlap (Figs 2 and 3). This implies that binding of Fabs at these
sites within an icosahedral asymmetric unit is mutually exclusive.
Only one Fab can be bound within an asymmetric unit, either
at the 2f or the 3f site. Furthermore, the footprint of the
2f site overlaps the footprint of the two-fold related 2f’ site
(Figs 2 and 3). Thus, similarly only one of the 2f or 2f0 sites can be
occupied at a time. Lastly the binding of Fab to the 2f0 and 3f0
sites is also mutually exclusive. Assuming that each binding site is
chemically identical and therefore equally likely to bind a Fab
molecule, there are three different possible arrangements of Fabs
that can bind to the overlapping 3f, 2f, 2f0 and 3f0 sites
(Supplementary Fig. 4). Inspection of Supplementary Fig. 4
shows that on average, the 3f and 3f0 sites will be occupied two
times out of every three randomly chosen particles, whereas the 2f
and 2f0 sites will be occupied only once out of three randomly
chosen particles. Thus, on average, the 3f site should have 67%
occupancy whereas the 2f site should have 33% occupancy.
The Fab occupancy at the 2f and 3f sites relative to the ZIKV
E protein was determined by the program EMﬁt, which calculates
the average electron density at the atomic centres of the ﬁtted
coordinates. The average heights of density of the Fabs bound at
the 2f and 3f sites were 35 and 58% respectively of the E protein
density (100% occupancy, Supplementary Table 1), which
correspond to 21 and 35 Fabs at the 2f and 3f sites. The missing
7% of Fabs is either because the average of all the particles used in
the EM reconstruction had less than 60 Fabs per particle or is
simply experimental error. Given the experimental conditions,
the observed occupancies are in excellent agreement with the
predicted 33 and 67% (Supplementary Fig. 4).
Discussion
The efﬁcacy of neutralization of ZIKV infection by ZIKV-117 is
in part due to the requirement of only 60 bound Fab molecules
instead of the anticipated stoichiometric 180 bound Fabs to
effectively cross-link the glycoprotein shell. In addition, the tight
binding of the Fab to the E protein is also a signiﬁcant
contributing factor. The footprints of the Fabs bound at the
2f and 3f sites consist primarily of polar residues of the E protein
















Figure 2 | Fab binding sites on ZIKV surface. The E proteins are
represented in three colours—blue (chains A, A0 and A00), red
(chains C, C0 and C00) and green (chains E, E0 and E00). Chains A and A0 are
arranged in a dimer around the icosahedral two-fold axis (blue oval with
black outline), while chains C and E are arranged in a general dimer around
a quasi two-fold axis (yellow oval with black outline). The icosahedral
and general dimers are related by an axis of quasi two-fold symmetry
(orange oval with black outline). Residues Asp67 (red), Gln89 (green) and
Lys118 (blue), which were mapped to the Fab binding site by mutagenesis,
are shown as spheres. The footprints of the Fab bound at the 2f and 3f sites
are represented as light and dark grey ovals with broken outlines. The black
stars mark the position of the fusion peptides. The steric hindrance on the
5f site due to the orientation of DIII of chain A00 is highlighted by black
arrows. For reference, two asymmetric units are shown as triangles in solid
and broken dashed lines. The icosahedral ﬁve- and three-fold axes are
marked with a pentagon and two triangles receptively.
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hydrogen bonds with the ZIKV-117 Fab to form strong, stable
virus-Fab interactions. In addition, the Fab footprints show that
ZIKV-117 cross-links E monomers within a dimer, and across
neighbouring dimers (Fig. 3). At the 2f site, the Fab cross-links
monomers A and A0 of the i2 dimer and monomer C of the
general q2 dimer (Figs 2 and 3). In contrast, the Fab bound at the
3f site cross-links monomers C and E of the general q2 dimer and
monomer A of the i2 dimer (Figs 2 and 3). Therefore, ZIKV-117
causes extensive intra-dimer as well as inter-dimer cross-linking
of the ZIKV E protein.
Antibodies that cross-link E proteins and neutralize infection
have been reported for ZIKV30, DENV31–35 and WNV36. These
antibodies cross-link DII with either DI or DIII, or with both
DI and DIII. The ZIKV-speciﬁc antibody binds to DIII at 120 of
180 sites, away from the E protein dimer axis30. A structure of
a DENV antibody bound to ZIKV shows that the antibody
binds at 180 sites on the virus particle to cross-link DI, DII and
DIII to prevent low pH triggered conformational changes of the
virus37. The epitopes of the cross-linking ZIKV, DENV and
WNV antibodies are not close to the i2 or q2 axes. Therefore, in
contrast to ZIKV-117, the binding of Fab to one site does not
exclude binding of Fab to another site. This implies that
antibodies that bind to sites on DII are likely to require a lower
concentration to saturate and neutralize the virus.
The ﬂavivirus E dimer is converted into a trimer upon viral
entry into host cells under acidic conditions in endosomes38–40.
These trimers expose the fusion peptides which insert themselves
into the endosomal membrane to form a channel across the
endosomal membrane for the transfer of the viral RNA genome
into the host’s cytosol41. Binding of the ZIKV-117 Fab at the
2f and 3f positions will inhibit the low-pH triggered rearrange-
ment of the E protein dimer into a fusogenic trimer inside the
host cell. This is supported by a pre-/post-neutralization assay of
ZIKV infection, which shows that the ZIKV-117 is able to
signiﬁcantly inhibit infection at a post-attachment, intra-cellular
step (Supplementary Fig. 5).
At acidic pH mature ﬂaviviruses undergo a major conforma-
tional change in which the E glycoproteins re-arrange themselves
to form 60 trimeric spikes42 with the fusion peptide in DII of
each monomer exposed at their distal extremity. This large
re-arrangement is likely to leave the virus lacking homogeneity
accounting for the decline in obtaining high resolution cryoEM
structures37. Inspection of Fig. 2 suggests various ways in which
the monomers might re-arrange themselves to extend radially
with their fusion peptides at the far end of the spikes away from
the virus centre. For instance, monomers A, C and E (Fig. 2) are
close together to form a spike, and monomers A0, C0 and E0 would
then be able to form a two-fold related spike. This would
allow the formation of one spike per icosahedral asymmetric
unit. However if monomers A0, A and C were to form a spike,
they would leave monomers E, C0, E0 without partners. This
would allow the formation of one spike for two icosahedral
asymmetric units. But acidiﬁcation of DENV results in the
formation of 60 spikes per particle, which is one spike per
asymmetric unit41. Therefore, the ﬁrst option mentioned here
is a more likely association of monomers that make a fusogenic
virus. As the overlap of ZIKV-117 Fab binding sites especially
emphasizes the cross linking of monomers A, C and E, it is
probable that the antibody will inhibit the formation of fusogenic
spikes. This also shows that the binding of 60 Fabs is enough to
inhibit 90 E dimers from making a spikey fusogenic structure.
Since the beginning of the 2013 ZIKV outbreak, emphasis has
been placed on the study of cross-reacting anti-DENV antibodies
for neutralizing ZIKV infection21,37,43–46. In vivo studies have
shown that anti-ZIKV antibodies that cross-react with DENV
may promote infection by antibody-dependent enhancement21.
The ZIKV-117 mAb does not bind any of the four DENV
serotypes or WNV20. An alignment of ﬂavivirus sequences shows
that the E protein residues that form the ZIKV-117 footprint are
poorly conserved across ﬂaviviruses (Supplementary Fig. 6a). In
contrast, the footprint of ZIKV-117 is largely conserved among
ZIKV strains (Supplementary Fig. 6b). Consistent with recent
functional data showing potent neutralization of ﬁve different
African, Asian and American strains of ZIKV, the ZIKV-117
mAb binds to a conserved ZIKV epitope and should therefore
provide broad-range protection against virtually all strains of
ZIKV.
In summary, considering that the surface of ZIKV is made of
60 copies of three environmentally different E monomers, it
would be expected that 180 copies of the Fab would be bound to
the ZIKV virion. Our study shows that contrary to expectation,
Fab binding at the 5f site is extremely weak despite no obvious
clashes between symmetry related Fabs around the ﬁve-fold axes.
We show that the epitope at the 5f site has limited accessibility
due to steric hindrance from a neighbouring E monomer.






Figure 3 | Footprints of ZIKV-117 Fabs on the E protein. The ﬁgure shows
a roadmap of the ZIKV E protein. The E protein residues are coloured
according to their distance from the virus centre, with the residues closer to
the centre coloured blue (218Å) and those farthest from the centre
coloured red (235Å). The colours of residues transition from blue to red
through green. The position of the icosahedral two-fold axis is marked with
a blue oval. The quasi two-fold axes are marked as orange or yellow ovals.
The outlines of the individual E protein chains are marked with thick
black lines, and the chains are labelled as per the convention described in
Fig. 2. The residues Asp67, Gln89 and Lys118 within the ZIKV-117 epitope
are highlighted with red lines. The ZIKV-117 footprints formed by E protein
residues that lie within 8Å of the bound Fab at the 2f (yellow outline) and
3f (white outline) sites are highlighted across the quasi two-fold axis
(orange oval). The footprints extend across multiple E proteins, and there
is signiﬁcant overlap between the footprints. At the 5f site, DIII of chain
A0 0 (highlighted with a white arrow) poses a steric barrier to the binding
of Fab.
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binding sites limits the occupancies of the 3f and 2f sites in
a predictable manner, implying that neutralization of the virus
can be achieved with a lower occupancy of antibodies compared
to what would be the case were the binding sites well separated.
The structure of the Fab-virus complex suggests that the antibody
functions by preventing the rearrangement of E proteins
necessary for low-pH mediated fusion.
Methods
Isolation of ZIKV-117 Fab fragments. MAb ZIKV-117 is a naturally occurring
fully human mAb isolated from a B cell in a peripheral blood sample obtained from
an otherwise healthy subject with previous history of symptomatic ZIKV infection.
The isolation and determination of the variable region sequences of the heavy and
light chains were described previously20. RT-PCR was performed with primers
having overlapping regions with the leader and constant domains47, and the
amplicons were cloned directly into immunoglobulin expression vector cassettes48
using a Gibson assembly kit (New England Biolabs). Plasmids encoding the heavy
or light chains were transfected transiently into Expi293 cells (Invitrogen), and
the secreted Fab protein was harvested from culture supernatant. Recombinant
Fab protein was concentrated and puriﬁed by afﬁnity chromatography using the
CaptureSelect IgG-CH1 matrix (Thermo Scientiﬁc) and further concentrated using
10 MWCO concentrators (Millipore).
CryoEM and 3D reconstruction. The ZIKV particles were incubated with the
ZIKV-117 Fab at 4 C for 2–3 h, and then ﬂash-frozen (2.5 ml) on lacey carbon
EM grids by plunging in liquid ethane using a Gatan Cp3 plunger. Micrographs
were recorded on a Gatan K2 direct electron detector, attached to a Titan-Krios
microscope at a magniﬁcation of  18,000 in the direct counting mode with a
pixel size of 1.62 Å. The total electron dose per image was B30 eÅ 2. The
automated software Leginon49 was used to collect 1,141 micrographs, of which 406
micrographs were rejected due to poor ice thickness, drift and errors in defocus. A
total of 38,835 particles of the Fab-virus complex were selected in Appion50 from
the remaining 735 micrographs, within a defocus range of  2.5 to  5.0 mm. The
38,853 particle set was then subjected to two rounds of non-referenced 2D-
classiﬁcation in RELION51 to generate a subset of 8,153 homogeneous Fab-virus
particles, which was split into two half data sets to perform two independent
3D-reconstructions for a ‘gold-standard’ evaluation of the resolution22. The
previously published ZIKV cryoEM map8 was low-pass ﬁltered to 50Å resolution,
and used as the initial model for single particle reconstruction by the program jspr
(ref. 23). During the initial stages of the reconstruction, the centre position and
orientation of each particle were reﬁned using projection matching, which was
followed by the reﬁnement of high-order parameters, that is, anisotropic
magniﬁcation, astigmatism, defocus and beam tilt52,53. A resolution of 6.2 Å was
assigned corresponding to a Fourier Shell Correlation coefﬁcient of 0.143
(Supplementary Fig. 1). The ﬁtting procedure for the E protein and Fab has been
described in the main text.
Pre- and post-attachment neutralization assays. For the pre-attachment assay,
serial dilutions of recombinant ZIKV-117 were pre-incubated with 102 FFU of
ZIKV Brazil Paraiba 2015 for 1 h at 4 C. The mAb-virus complexes then were
added to Vero cell monolayers in 96-well plates for 1 h at 4 C. For the post-
attachment assay, 102 FFU of ZIKV Brazil Paraiba 2015 was added to a Vero cell
monolayer in 96-well plates for 1 h at 4 C. Unbound virus was removed followed
by serial washes with Dulbecco’s modiﬁed Eagle medium (DMEM), and then
dilutions of recombinant ZIKV-117 were added for 1 h at 4 C. Subsequently, all
cells were washed three times with DMEM, incubated in DMEM supplemented
with 5% FBS at for 1 h at 37 C, and then overlaid with 1% (w/v) methylcellulose in
a-MEM supplemented with 4% heat-inactivated FBS. Plates were ﬁxed 40 h later
with 1% paraformaldehyde in PBS for 1 h at room temperature. The plates were
incubated sequentially with 500 ngml 1 mouse anti-ZIKV (ZV-16, E. Fernandez
and M. Diamond, unpublished) and HRP-conjugated goat anti-mouse IgG in
PBS supplemented with 0.1% (w/v) saponin (Sigma) and 0.1% BSA. ZIKV-infected
cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated
on an ImmunoSpot 5.0.37 macroanalyzer (Cellular Technologies).
Sequence alignments. The sequences of ﬂavivirus ZIKV E protein were obtained
from GenBank. Alignment of E protein sequences was performed using the
program Clustal-Omega54 and ﬁgures were prepared using the program ESpript55.
Data availability. The cryoEM map and ﬁtted coordinates of the ZIKV/ZIKV-117
complex have been deposited in the Electron Microscopy Data Bank and the
Protein Data Bank under the accession codes EMD-8548 and 5UHY respectively.
The data that support the ﬁndings of this study are available from the corre-
sponding author on request. Requests for antibody material should be addressed to
james.crowe@vanderbilt.edu.
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